The Board of Lupin at its meeting held on 11 February 2025 has approved the transfer of the over-the-counter (OTC) Consumer Healthcare business of the company, on a slump sale basis, to a wholly owned subsidiary that is proposed to be incorporated.
The Board also approved the incorporation of a wholly owned subsidiary in the name and style “LUPINLIFE Consumer Healthcare” or any other appropriate name, as may be approved by the Ministry of Corporate Affairs.